A Phase 2 interventional study of Fluticasone Furoate and FF/Vilanterol (VI; GW642444M) in Asthma, sponsored by GlaxoSmithKline. Completed at 4 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-18.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.
Among the 40 studies testing fluticasone furoate in Asthma, this one is the 24th largest by enrollment, is one of 7 that started in 2010, is one of 12 in phase 2, and was the 12th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 102 across the 40 interventional studies. Of the 35 that completed or were terminated, 22 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 40 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 145th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 59 in phase 2, and was the 91st registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing fluticasone furoate in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing fluticasone furoate in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist (LABA)/ inhaled corticosteroid (ICS) combination product on protection from allergic triggers in asthma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo Inhaler
Drug: Placebo
ICS/LABA inhaler
Drug: FF/Vilanterol (VI; GW642444M)
ICS inhaler
Drug: Fluticasone Furoate
FF
Also known as: FF
Drug page: Vilanterol
FF/VI
Also known as: FF/VI
Placebo Inhaler
Weighted Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Between 0-2 Hours, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants (par.) were exposed to an allergen (administered by inhalation) 22-23 hours after dosing on Day 28. FEV1 was measured 5 minutes (min), 10 min, 15 min, 20 min, 30 min, and 45 min and 1 hour, 1.5 hours, and 2 hours post-allergen challenge on Day 29. Immediately prior to the exposure of allergen and starting at 2 minutes after inhalation of saline, 3 single measurements of FEV1 were recorded at 1-minute intervals, and the best was taken as the post-saline value. The FEV1 weighted mean was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. Weighted mean change from Baseline is calculated as the weighted mean FEV1 value on Day 29 minus the Baseline value. The Baseline FEV1 value was the post-saline value on Day 29.
Time frame: Baseline and Day 29 of each treatment period (up to Study Day 197)
Maximum Percent Decrease From Baseline in FEV1 Between 0 2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 22-23 hours after dosing on Day 28. Immediately prior to the exposure of allergen and starting at 2 minutes (min) after inhalation of saline, 3 single measurements of FEV1were recorded at 1-min intervals, and the best was taken as the post-saline value. The maximum change (i.e., drop in FEV1) from post-saline Baseline (BL) is defined by ordering all of the change from BL values for the 5 min, 10 min, 15 min, 20 min, 30 min, and 45 min and the 1 hour, 1.5 hours, and 2 hours post-allergen challenge and selecting the largest change (i.e., drop in FEV1) from the BL value. If there were no negative change values, indicating a worse FEV1 value as compared to the BL value, the smallest change in FEV1, indicating an improvement from the BL value, was selected. The BL FEV1 value was the post-saline value on Day 29.
Time frame: Baseline and Day 29 of each treatment period (up to Study Day 197)
Minimum FEV1 Absolute Change From Baseline Between 0-2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 22-23 hours after dosing on Day 28. Immediately prior to the exposure of allergen and starting at 2 minutes after inhalation of saline, 3 single measurements of FEV1were recorded at 1-minute intervals, and the best was taken as the post-saline value. The minimum FEV1 over 0-2 hours post-allergen challenge (PAC) (minimum early asthmatic response) was the minimum value of all of the PAC time points up to and including 2 hours PAC (i.e., minimum over 5 minutes (min), 10 min, 15 min, 20 min, 30 min, and 45 min and 1 hour, 1.5 hours, and 2 hours). Change from Baseline was calculated using the post-saline FEV1 on Day 29 as Baseline. Minimum FEV1 absolute change from Baseline between 0-2 hour, following the 22-23 hour post-treatment allergen challenge was calculated as the minimum change value on Day 29 minus the Baseline value
Time frame: Baseline and Day 29 of each treatment period (up to Study Day 197)
Number of Participants With Treatment-emergent Adverse Events (AEs)
The number of participants with treatment-emergent AEs was measured. A treatment-emergent adverse event is defined as any event not present prior to the initiation of the treatments, or any event already present that worsens in either intensity of frequency following exposure to the treatments.
Time frame: From the start of study medication until Follow-up/Early Withdrawal (up to 197 days)
Participants were screened within 42 days of the first dose, conducted over 2 days (not consecutive days). During this time, a methacholine challenge and an allergen challenge test were performed. Participants meeting all inclusion criteria and none of the exclusion criteria were randomized to 3 study treatment periods, each lasting 28 days.
| Milestone | Sequence 1: Placebo, FF 100 µg, FF/VI 100/25 µg | Sequence 2: Placebo, FF/VI 100/25 µg, FF 100 µg | Sequence 3: FF 100 µg, FF/VI 100/25 µg, Placebo | Sequence 4: FF 100 µg, Placebo, FF/VI 100/25 µg | Sequence 5: FF/VI 100/25 µg, Placebo, FF 100 µg | Sequence 6: FF/VI 100/25 µg, FF 100 µg, Placebo |
|---|---|---|---|---|---|---|
| Started | 9 | 8 | 9 | 8 | 9 | 9 |
| Completed | 9 | 8 | 9 | 8 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: Placebo, FF 100 µg, FF/VI 100/25 µg | Sequence 2: Placebo, FF/VI 100/25 µg, FF 100 µg | Sequence 3: FF 100 µg, FF/VI 100/25 µg, Placebo | Sequence 4: FF 100 µg, Placebo, FF/VI 100/25 µg | Sequence 5: FF/VI 100/25 µg, Placebo, FF 100 µg | Sequence 6: FF/VI 100/25 µg, FF 100 µg, Placebo |
|---|---|---|---|---|---|---|
| Started | 9 | 8 | 9 | 8 | 9 | 9 |
| Completed | 9 | 8 | 8 | 8 | 9 | 9 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Sequence 1: Placebo, FF 100 µg, FF/VI 100/25 µg | Sequence 2: Placebo, FF/VI 100/25 µg, FF 100 µg | Sequence 3: FF 100 µg, FF/VI 100/25 µg, Placebo | Sequence 4: FF 100 µg, Placebo, FF/VI 100/25 µg | Sequence 5: FF/VI 100/25 µg, Placebo, FF 100 µg | Sequence 6: FF/VI 100/25 µg, FF 100 µg, Placebo |
|---|---|---|---|---|---|---|
| Started | 9 | 8 | 8 | 8 | 9 | 9 |
| Completed | 9 | 7 | 8 | 8 | 9 | 9 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: Placebo, FF 100 µg, FF/VI 100/25 µg | Sequence 2: Placebo, FF/VI 100/25 µg, FF 100 µg | Sequence 3: FF 100 µg, FF/VI 100/25 µg, Placebo | Sequence 4: FF 100 µg, Placebo, FF/VI 100/25 µg | Sequence 5: FF/VI 100/25 µg, Placebo, FF 100 µg | Sequence 6: FF/VI 100/25 µg, FF 100 µg, Placebo |
|---|---|---|---|---|---|---|
| Started | 9 | 7 | 8 | 8 | 9 | 9 |
| Completed | 9 | 7 | 8 | 8 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: Placebo, FF 100 µg, FF/VI 100/25 µg | Sequence 2: Placebo, FF/VI 100/25 µg, FF 100 µg | Sequence 3: FF 100 µg, FF/VI 100/25 µg, Placebo | Sequence 4: FF 100 µg, Placebo, FF/VI 100/25 µg | Sequence 5: FF/VI 100/25 µg, Placebo, FF 100 µg | Sequence 6: FF/VI 100/25 µg, FF 100 µg, Placebo |
|---|---|---|---|---|---|---|
| Started | 9 | 7 | 8 | 8 | 9 | 9 |
| Completed | 9 | 7 | 8 | 8 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants (par.) were exposed to an allergen (administered by inhalation) 22-23 hours after dosing on Day 28. FEV1 was measured 5 minutes (min), 10 min, 15 min, 20 min, 30 min, and 45 min and 1 hour, 1.5 hours, and 2 hours post-allergen challenge on Day 29. Immediately prior to the exposure of allergen and starting at 2 minutes after inhalation of saline, 3 single measurements of FEV1 were recorded at 1-minute intervals, and the best was taken as the post-saline value. The FEV1 weighted mean was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. Weighted mean change from Baseline is calculated as the weighted mean FEV1 value on Day 29 minus the Baseline value. The Baseline FEV1 value was the post-saline value on Day 29.
| Liters | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Weighted Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Between 0-2 Hours, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period | -0.372 ± 0.0557 | -0.210 ± 0.0549 | -0.227 ± 0.0550 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 22-23 hours after dosing on Day 28. Immediately prior to the exposure of allergen and starting at 2 minutes (min) after inhalation of saline, 3 single measurements of FEV1were recorded at 1-min intervals, and the best was taken as the post-saline value. The maximum change (i.e., drop in FEV1) from post-saline Baseline (BL) is defined by ordering all of the change from BL values for the 5 min, 10 min, 15 min, 20 min, 30 min, and 45 min and the 1 hour, 1.5 hours, and 2 hours post-allergen challenge and selecting the largest change (i.e., drop in FEV1) from the BL value. If there were no negative change values, indicating a worse FEV1 value as compared to the BL value, the smallest change in FEV1, indicating an improvement from the BL value, was selected. The BL FEV1 value was the post-saline value on Day 29.
| Percent change | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Maximum Percent Decrease From Baseline in FEV1 Between 0 2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period | -24.991 ± 2.0736 | -14.040 ± 2.0435 | -13.206 ± 2.0491 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 22-23 hours after dosing on Day 28. Immediately prior to the exposure of allergen and starting at 2 minutes after inhalation of saline, 3 single measurements of FEV1were recorded at 1-minute intervals, and the best was taken as the post-saline value. The minimum FEV1 over 0-2 hours post-allergen challenge (PAC) (minimum early asthmatic response) was the minimum value of all of the PAC time points up to and including 2 hours PAC (i.e., minimum over 5 minutes (min), 10 min, 15 min, 20 min, 30 min, and 45 min and 1 hour, 1.5 hours, and 2 hours). Change from Baseline was calculated using the post-saline FEV1 on Day 29 as Baseline. Minimum FEV1 absolute change from Baseline between 0-2 hour, following the 22-23 hour post-treatment allergen challenge was calculated as the minimum change value on Day 29 minus the Baseline value
| Liters | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Minimum FEV1 Absolute Change From Baseline Between 0-2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period | -0.809 ± 0.0775 | -0.479 ± 0.0765 | -0.478 ± 0.0767 |
The number of participants with treatment-emergent AEs was measured. A treatment-emergent adverse event is defined as any event not present prior to the initiation of the treatments, or any event already present that worsens in either intensity of frequency following exposure to the treatments.
| participants | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (AEs) | 20 | 22 | 18 |
Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication until Follow-up/Early Withdrawal (up to 197 days).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/51 (0%) | 15/51 (29.4%) |
| FF 100 µg OD | — | 0/51 (0%) | 18/51 (35.3%) |
| FF/VI 100/25 µg OD | — | 0/51 (0%) | 11/51 (21.6%) |
| Event | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| HeadacheNervous system disorders | 9/51 | 11/51 | 5/51 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/51 | 3/51 | 0/51 |
| NasopharyngitisInfections and infestations | 3/51 | 2/51 | 0/51 |
| Chest discomfortGeneral disorders | 3/51 | 0/51 | 0/51 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/51 | 2/51 | 2/51 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 0/51 | 2/51 | 2/51 |
| Mouth ulcerationGastrointestinal disorders | 0/51 | 2/51 | 2/51 |
| NauseaGastrointestinal disorders | 2/51 | 2/51 | 0/51 |
| Age, Continuous(Years) | Placebo, FF 100 µg OD, FF/VI 100/25 µg OD in 1 of 6 Sequences |
|---|---|
| Mean | 35.4 ± 8.63 |
| Gender(Participants) | Placebo, FF 100 µg OD, FF/VI 100/25 µg OD in 1 of 6 Sequences |
|---|---|
| Female | 18 |
| Male | 34 |
| Race/Ethnicity, Customized(participants) | Placebo, FF 100 µg OD, FF/VI 100/25 µg OD in 1 of 6 Sequences |
|---|---|
| White - White/Caucasian/European Heritage | 48 |
| African American/African Heritage | 2 |
| Asian - South East Asian Heritage | 1 |
| Mixed Race | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jan 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 2 years 11 months after primary completion. A results delay was requested in Mar 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone furoate · Vilanterol